Horm Metab Res 1999; 31(11): 602-605
DOI: 10.1055/s-2007-978804
Originals Clinical

© Georg Thieme Verlag Stuttgart · New York

Increased Urinary Phosphate Excretion in Pseudohypoparathyroidism Type II with Long-Term Treatment with Phosphodiesterase Inhibitor

T. Mano1 , K. Uchimura1 , R. Hayashi1 , T. Kobahashi1 , K. Fujiwara1 , M. Makino1 , H. Kakizawa1 , M. Nagata1 , A. Nakai1 , M. Wada2 , A. Nagasaka1 , M. Itoh1
  • 1Departments of Internal Medicine, Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
  • 2Wada Hospital, Nagoya, Aichi, Japan
Further Information

Publication History



Publication Date:
20 April 2007 (online)

A 58-year-old woman was diagnosed to have pseudohypoparathyroidism (PHP) type II because of the absence of an increase of urinary phosphate secretion, despite a marked increase in urinary cAMP excretion on the Ellsworth-Howard test. We treated the patient with a cyclic-nucleotide phosphodiesterase inhibitor, theophylline, resulting in increased urinary phosphate and cAMP excretions. Dibutyl cAMP administration induced the increase in the urinary phosphate excretion. In this case, the unresponsiveness of the urinary phosphate secretion to cAMP was recovered by a high dose of cAMP or long-term administration of a phosphodiesterase inhibitor. These data imply that cAMP responsiveness to renal tubular phosphate reab-sorption should be more strictly elucidated in the patient with PHP type II.